CD30-directed Immunoconjugate [EPC]

10402 reported adverse events

Drugs of this class: BRENTUXIMAB VEDOTIN

These side effects are most commonly reported by patients taking drugs of the CD30-directed Immunoconjugate [EPC] class:

# Side effect Count
0 OFF LABEL USE 1358
1 FEBRILE NEUTROPENIA 776
2 NEUROPATHY PERIPHERAL 725
3 PYREXIA 694
4 NEUTROPENIA 599
5 DEATH 594
6 HODGKIN^S DISEASE 462
7 NAUSEA 407
8 ANAEMIA 399
9 THROMBOCYTOPENIA 388
See all common reactions for CD30-directed Immunoconjugate [EPC]

Drugs of the CD30-directed Immunoconjugate [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 ANAPLASTIC LARGE-CELL LYMPHOMA 86 0.3644
1 PERIPHERAL T-CELL LYMPHOMA UNSPECIFIED 92 0.1551
2 PERIPHERAL SENSORY NEUROPATHY 145 0.0248
3 PRODUCT TEMPERATURE EXCURSION ISSUE 94 0.0183
4 POLYNEUROPATHY 213 0.0178
5 PNEUMOCYSTIS JIROVECII PNEUMONIA 142 0.0141
6 FEBRILE NEUTROPENIA 776 0.0117
7 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 73 0.0088
8 NEUROPATHY PERIPHERAL 725 0.0076
9 MYELOSUPPRESSION 259 0.0072
See all enriched reactions for CD30-directed Immunoconjugate [EPC]